Recombinant Human ACAT1 Protein His-tag Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Acetyl-CoA acetyltransferase-1 (ACAT1), also known as T2 or 3-ketothiolase, is a ubiquitous metabolic enzyme that catalyzes the potassium-regulated reversible thiolytic cleavage of fatty acids to form acetyl-CoA and a fatty acid acyl-CoA or condensation of two acetyl-CoA molecules into acetoacetyl-CoA (1). Human ACAT1 is a member of the thiolase superfamily and forms a homotetramer composed of a dimer of dimers due to an extended protruding loop (2). Each subunit contains an N-terminal domain including the dimer interface and a reactive cysteine while the C-terminal domain contains a catalytic pair that interacts with the N-terminal cysteine to create a catalytic triad (2).  ACAT1 is known to be catalytically involved in isoleucine degradation, ketolysis, ketogenesis and fatty acid oxidation (3). Several mutations in the ACAT1 gene have been identified that lead to ACAT1 deficiency as an autosomal recessive inherited disorder known as 3-ketothiolase deficiency (3KTD) (4, 5).  3KTD is characterized by isoleucine degradation and defects in ketone body metabolism (6). More recently, ACAT1 has been shown to be involved in metabolic dysregulation in cancer through a role in drug resistance, cancer cell proliferation and tumor growth (3, 7-9).  ACAT1 has been found to be upregulated as a potential prognostic marker in prostate cancer (3, 10) while overexpression of ACAT1 in breast cancer cells showed ACAT1's role in promoting tumor growth and metastasis through ketone body re-utilization (3, 11). ACAT1 inhibitors have been shown to inhibit proliferation of cancer stem cells (7, 12) possibly through inhibition of the ACAT1 acetyltransferase activity targeting pyruvate dehydrogenase and pyruvate dehydrogenase phosphatase (7) thus making ACAT1 a potential therapeutic target in cancer (3, 7, 11, 12).

Array 10242-AC

• ACAT1 Antibodies
• ACAT1 Proteins
• ACAT1 Proteins and Enzyme